Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

The 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) will be taking place virtually from May 12-15, 2020. Intellia Therapeutics Inc., a company specializing in genome editing using CRISPR/Cas9, announced that five poster abstracts have been accepted for presentation at this meeting. One specific poster, titled "In Vivo Model Development for Genome-Edited T Cell Therapeutics", demonstrates the use of improved murine models to assess safety, efficacy, and persistence of therapeutic modalities in cell-based therapies. Taconic Biosciences partnered with Intellia Therapeutics to develop two in vivo mouse models, which enabled enhanced monitoring of graft-versus-host disease (GvHD) and human natural killer cytotoxicity.

Read the complete article at: businesstelegraph.co.uk